Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4
DK Hansen, X Lu, OC Puglianini, S Sorensen… - Frontiers in …, 2024 - frontiersin.org
Introduction Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell
therapy approved for patients with relapsed/refractory multiple myeloma (RRMM). In the …
therapy approved for patients with relapsed/refractory multiple myeloma (RRMM). In the …
Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma
Introduction Chimeric antigen receptor (CAR) T-cell therapy (CAR T therapy) is a treatment
option for patients with relapsed or refractory multiple myeloma that has led to …
option for patients with relapsed or refractory multiple myeloma that has led to …